Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis

Slide: 27 of 37

Potential Harms of rhGH Treatment to Patients With CF: Glucose Control and CFRD (2)

Fasting blood glucose during treatment was elevated by 5.7mg/dL on average.  Hemoglobin A1c was unaffected by rhGH treatment but the evidence quality is low.  Evidence about random, postprandial and stimulated glucose levels is insufficient to estimate an effect.

Although CFRD developed in 3 patients during the course of treatment in trials where this event was monitored, the evidence is insufficient to evaluate the contribution of rhGH to these outcomes.